# AI赋能制药研发：从噱头到落地的实质性突破

- 来源：Chubby♨️ (@kimmonismus)
- 发布时间：2026-05-19 23:36
- AIHOT 分数：56
- AIHOT 链接：https://aihot.virxact.com/items/cmpctiwz9007qsl50xqjq12gd
- 原文链接：https://x.com/kimmonismus/status/2056760942378266763

## AI 摘要

过去三年，主流药企的AI合作大多停留在公关层面，未实质改变研发流程。Edison Scientific为Incyte部署的Kosmos系统是例外：它作为生产级工具，单次运行可处理1500篇文献并生成42,000行代码，且结果具有79%的可复现性，结论均可溯源。这标志着AI首次从理论演示进入实际研发管线，真正压缩研发周期，有望加速新药问世进程。

## 正文

Every major pharma company announced an AI partnership in the last three years. Most of them changed nothing.

The press release went out， the stock moved， and the actual R&D pipeline stayed exactly the same.

Edison Scientific just deployed Kosmos across Incyte's full pipeline. Not a pilot. Not a proof of concept. A production system that reads 1，500 papers and writes 42，000 lines of code in a single run！

The difference between this and everything that came before it： receipts. 79% reproducibility. Every conclusion traceable to a specific paper or line of code.

This is the first time I'm looking at an AI deployment in pharma and thinking： this actually changes how drugs get made. Not in theory， or in a pitch deck - but in production， right now， across an entire R&D pipeline.

If AI can compress six months of scientific work into a single day with this level of traceability， the implications for how fast treatments reach patients are massive.